Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060359 · ClinicalTrials.gov registry record · Phase 1
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00060359 is a Phase 1 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 32 participants.
The verdict
NCT00060359, a Phase 1 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of polyglutamate paclitaxel when given together with carboplatin in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer. Drugs used in chemotherapy such as polyglutamate paclitaxel and carboplatin use different ways to stop tumor cells from dividing so they stop growing or die. Polyglutamate paclitaxel may be able to deliver the drug directly to tumor cells while leaving normal cells undamaged. Combining polyglutamate paclitaxel with carboplatin may kill more tumor cells.
Interventions
- DRUG Carboplatin
- OTHER Pharmacological Study
- DRUG Paclitaxel Poliglumex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060359
The ClinicalTrials.gov registry entry for NCT00060359 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00060359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060359 about?
NCT00060359 is a clinical study titled "Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer". This phase I trial is studying the side effects and best dose of polyglutamate paclitaxel when given together with carboplatin in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer. Drugs used in chemotherapy such as polyglutamate paclitaxel and carboplatin use different...
What is the current status of trial NCT00060359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2003-04.
What interventions are being tested in trial NCT00060359?
The interventions under investigation include: Carboplatin (DRUG), Pharmacological Study (OTHER), Paclitaxel Poliglumex (DRUG).
Who is sponsoring clinical trial NCT00060359?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.